The definition and meaning of treatment-resistant depression.

Most patients treated for an episode of unipolar or bipolar major depression are treatment resistant in the sense that the majority do not achieve full remission with the first somatic or psychosocial treatment they receive. Little attention has been given to formalizing criteria for evaluating the nature and extent of treatment resistance, even though determining the adequacy and outcome of prior treatment trials is key in clinical decision making about subsequent treatment. Furthermore, determining the adequacy of prior treatment is essential since substantial evidence indicates that large numbers of depressed patients are undertreated, resulting in prolonged episodes and the appearance of "pseudoresistance." Adequacy of antidepressant treatment trials should be defined in terms of thresholds for the dosage and duration of medication, adherence, and clinical outcome. The Antidepressant Treatment History Form is presented as one method to formalize the evaluation of treatment adequacy and treatment resistance.

[1]  J. Markowitz,et al.  A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. , 2000, The New England journal of medicine.

[2]  S H Lisanby,et al.  A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. , 2000, Archives of general psychiatry.

[3]  G. Sachs,et al.  The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. , 2000, Postgraduate medicine.

[4]  P. Mitchell,et al.  Lamotrigine in the treatment of bipolar depression , 1999, European Neuropsychopharmacology.

[5]  J. Calabrese,et al.  Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. , 1999, The American journal of psychiatry.

[6]  Yvette I. Sheline,et al.  Depression Duration But Not Age Predicts Hippocampal Volume Loss in Medically Healthy Women with Recurrent Major Depression , 1999, The Journal of Neuroscience.

[7]  W. Coryell,et al.  Course of treatment received by depressed patients. , 1999, Journal of psychiatric research.

[8]  J. Calabrese,et al.  The efficacy of lamotrigine in rapid cycling and non–rapid cycling patients with bipolar disorder , 1999, Biological Psychiatry.

[9]  J. Amsterdam,et al.  Treatment resistant depression: methodological overview and operational criteria , 1999, European Neuropsychopharmacology.

[10]  M. Thase,et al.  Low use of neuroleptic drugs in the treatment of psychotic major depression. , 1997, The American journal of psychiatry.

[11]  M. Thase,et al.  The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. , 1997, JAMA.

[12]  R. D. McColl,et al.  Management options for refractory depression. , 1996, The American journal of medicine.

[13]  A. Awad,et al.  Psychopharmacology: The Fourth Generation of Progress , 1998, CNS Spectrums.

[14]  F. Quitkin,et al.  Can the Effects of Antidepressants Be Observed in the First Two Weeks of Treatment? , 1996, Neuropsychopharmacology.

[15]  H. Sackeim,et al.  Resistance to antidepressant medications and short-term clinical response to ECT. , 1996, The American journal of psychiatry.

[16]  G. Giorgetti,et al.  [Pharmacological treatment of delusional depression]. , 1996, Minerva psichiatrica.

[17]  J. Lonnqvist,et al.  Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression , 1995, Acta psychiatrica Scandinavica.

[18]  J. Lonnqvist,et al.  Antidepressant efficacy and quality of life in depression: a double‐blind study with moclobemide and fluoxetine , 1994, Acta psychiatrica Scandinavica.

[19]  H. Sackeim,et al.  The Impact of Medication Resistance and Continuation Pharmacotherapy on Relapse following Response to Electroconvulsive Therapy in Major Depression , 1990, Journal of clinical psychopharmacology.

[20]  H. Sackeim,et al.  Medication resistance and clinical response to electroconvulsive therapy , 1990, Psychiatry Research.

[21]  J. Stewart,et al.  Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo. , 1989, Archives of general psychiatry.

[22]  D. Klein,et al.  Antidepressant specificity in atypical depression. , 1988, Archives of general psychiatry.

[23]  P. Jatlow,et al.  Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. , 1986, The American journal of psychiatry.

[24]  IN Teens,et al.  MANIC-DEPRESSIVE ILLNESS , 1986, The Lancet.

[25]  G. Klerman,et al.  Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. , 1986, Archives of general psychiatry.

[26]  J. Rabkin,et al.  Duration of antidepressant drug treatment. What is an adequate trial? , 1984, Archives of general psychiatry.

[27]  G. Klerman,et al.  Treatment received by depressed patients. , 1982, JAMA.

[28]  M. Åsberg.  Plasma nortriptyline levels—relationship to clinical effects , 1974, Clinical pharmacology and therapeutics.

[29]  A. Nierenberg,et al.  Declaration of treatment failures. , 1997, Modern problems of pharmacopsychiatry.

[30]  D. Hadzi-Pavlovic,et al.  Psychotic (delusional) depression: a meta-analysis of physical treatments. , 1992, Journal of affective disorders.

[31]  The Practice of ECT: Recommendations for Treatment, Training and Privileging. , 1990, Convulsive therapy.

[32]  D. Kupfer,et al.  Continuation drug therapy for major depressive episodes: how long should it be maintained? , 1986, The American journal of psychiatry.

[33]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[34]  T. Cooper,et al.  The treatment of affective disorders in the elderly. , 1983, Psychopharmacology bulletin.

[35]  M. Åsberg,et al.  On the role of plasma level monitoring of tricyclic antidepressants in clinical practice. , 1978, Communications in psychopharmacology.